Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Indiana University
How would you approach a patient with grade 1/2 pancreatic neuroendocrine tumor after progressing on octreotide?
What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?
Answer from: Medical Oncologist at Community Practice
Tem/cape -- responses are good for pancreatic NET. PRRT Is great but so expensive. I’m finding it so hard to get.
Sign In
or
Register
to read more
6227
Related Questions
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
Would you offer adjuvant therapy to a patient with a high grade mucinous appendiceal neoplasm that is pT3 pN0 M0, >12 lymph nodes removed with ileocecectomy?
What systemic therapy would you use in patients with gastric cancer who had a relapse after Durva-FLOT (MATTERHORN regimen)?
With recent PFS data from LEAP-012 and Emerald-1, do you routinely offer for patients with intermediate BCLC stage HCC undergoing TACE or TARE systemic therapy (pembro/lenva or durve/bev)?
Are you using Tarlatamab for neuroendocrine carcinomas (NECs) and poorly differentiated neuroencocrine tumors of GI (non-lung) origins?
Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?
How does the presence of CNS disease affect your choice of first line therapy in Her2+ gastric adenocarcinoma?
What are your top takeaways in GI Cancers from ESMO 2025?
What adjuvant treatment approach would you recommend for a patient with early-stage MSI-high gastric cancer who received neoadjuvant ipilimumab (×2) and nivolumab (×6) per the NEONIPIGA regimen, followed by R0 resection with no pathologic response?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?